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ALT

:   alanine aminotransferase

CCL2

:   C‐C motif chemokine 2

CCR2

:   C‐C chemokine receptor type 2

GeSP

:   germanium straight‐chain polymer

HBV

:   hepatitis B virus

MDSC

:   myeloid‐derived suppressor cell

Mo‐MDSC

:   monocytic myeloid‐derived suppressor cell

PDAC

:   pancreatic ductal adenocarcinoma

PGe

:   propagermanium

RGe

:   repagermanium

TAM

:   tumor‐associated macrophage

1. INTRODUCTION {#cas14075-sec-0001}
===============

Inflammation is associated with the development of many diseases including cancer.[1](#cas14075-bib-0001){ref-type="ref"}, [2](#cas14075-bib-0002){ref-type="ref"} Under normal physiological conditions, the immune system eliminates pathogens and unwanted cells such as those that are damaged, senescent, or immature. However, cancer hijacks this system to ensure tumor survival and long‐term growth. Cancer cells recruit immune cells such as macrophages, neutrophils, and MDSC to form a microenvironment known as a "niche."[3](#cas14075-bib-0003){ref-type="ref"} Cancer cells and their niche cells produce various cytokines, chemokines, growth factors, ECM proteins, and proteases that promote tumor growth and metastasis.

C‐C motif chemokine 2 (CCL2, also known as monocyte chemoattractant protein 1) and its receptor CCR2 have attracted much interest in recent years because of their relation to cancer progression.[4](#cas14075-bib-0004){ref-type="ref"}, [5](#cas14075-bib-0005){ref-type="ref"} Although CCL2 was first described as a cytokine with a physiological role in the regulation of inflammation,[6](#cas14075-bib-0006){ref-type="ref"}, [7](#cas14075-bib-0007){ref-type="ref"} more recent studies have shown a protumorigenic function of CCL2 in the promotion of cancer development and metastasis (Figure [1](#cas14075-fig-0001){ref-type="fig"}). Binding of CCL2 to CCR2, a G protein‐coupled receptor, triggers intracellular signaling in cancer and other cell types. CCL2‐CCR2 signaling promotes cancer progression by supporting cancer cell proliferation and survival, inducing cancer cell migration and invasion, and stimulating inflammation and angiogenesis.[8](#cas14075-bib-0008){ref-type="ref"} CCL2 is secreted by many cell types including endothelial cells, fibroblasts, monocytes, and cancer cells, whereas CCR2 is expressed at a high level in inflammatory monocytes, dendritic cells, and natural killer cells as well as at a low level in neutrophils and T and B lymphocytes. In the early stages of metastasis, CCL2 guides tumor cell migration by interacting with CCR2 expressed on the surface of cancer cells.[9](#cas14075-bib-0009){ref-type="ref"}, [10](#cas14075-bib-0010){ref-type="ref"} CCL2 also induces expression of MMP2 and MMP9 in cancer cells, both of which facilitate cancer cell invasion,[11](#cas14075-bib-0011){ref-type="ref"}, [12](#cas14075-bib-0012){ref-type="ref"} and it promotes the intra‐ and extravasation of cancer cells by attracting TAM.[13](#cas14075-bib-0013){ref-type="ref"} TAM and MDSC recruited by CCL2 trigger an angiogenic switch[14](#cas14075-bib-0014){ref-type="ref"}, [15](#cas14075-bib-0015){ref-type="ref"} and suppress immune‐mediated attack of cancer cells.[16](#cas14075-bib-0016){ref-type="ref"} In addition, CCL2 attracts cancer cells to future sites of metastasis and supports their proliferation and survival at such premetastatic niches.[17](#cas14075-bib-0017){ref-type="ref"}

![Role of chemokine C‐C motif chemokine 2--C‐C chemokine receptor type 2 (CCL2‐CCR2) signaling in cancer progression. CCL2 is secreted by cancer cells and surrounding stromal cells. It induces tumor cell proliferation at the primary tumor site, and CCR2^+^ myeloid cells attracted by CCL2 suppress immune‐mediated killing of tumor cells. CCL2 also promotes tumor cell migration and invasion into the surrounding ECM followed by tumor cell intravasation into the circulation. The subsequent dissemination of cancer cells is directed by a chemotactic gradient of CCL2 toward potential sites of metastasis. CCL2 and CCR2^+^ cells then promote tumor cell extravasation and colonization and growth at such metastatic sites](CAS-110-2090-g001){#cas14075-fig-0001}

Increased levels of CCL2 in tumor cells or serum have been detected in individuals with melanoma or with breast, prostate, colorectal, gastric, or ovarian cancer, and they are frequently associated with disease progression, tumor grade, or metastasis, suggestive of the clinical importance of the CCL2‐CCR2 signaling pathway.[18](#cas14075-bib-0018){ref-type="ref"}, [19](#cas14075-bib-0019){ref-type="ref"}, [20](#cas14075-bib-0020){ref-type="ref"}, [21](#cas14075-bib-0021){ref-type="ref"}, [22](#cas14075-bib-0022){ref-type="ref"}, [23](#cas14075-bib-0023){ref-type="ref"}, [24](#cas14075-bib-0024){ref-type="ref"}, [25](#cas14075-bib-0025){ref-type="ref"}, [26](#cas14075-bib-0026){ref-type="ref"}, [27](#cas14075-bib-0027){ref-type="ref"} These observations also suggest that targeting of the CCL2‐CCR2 axis might be an effective strategy for cancer treatment.

Herein, we review currently available agents that target the CCL2‐CCR2 axis and studies of their efficacy for cancer treatment. Among such agents, we focus on an organogermanium compound, PGe (3‐oxygermylpropionic acid polymer), that has been shown to act as a blocker of CCR2 signaling.

2. INHIBITORS OF THE CCL2‐CCR2 AXIS {#cas14075-sec-0002}
===================================

2.1. Antibodies to CCL2 and CCR2 {#cas14075-sec-0003}
--------------------------------

Experimental studies and clinical information have implicated the CCL2‐CCR2 axis in tumor promotion and suggested that its inhibition might be of therapeutic value. One approach to inhibition of this axis is the administration of neutralizing antibodies to CCL2, which has been shown to suppress the growth of tumors formed by transplanted human prostate,[28](#cas14075-bib-0028){ref-type="ref"}, [29](#cas14075-bib-0029){ref-type="ref"} breast,[30](#cas14075-bib-0030){ref-type="ref"} or pancreatic[31](#cas14075-bib-0031){ref-type="ref"} cancer cells in mice as well as to attenuate macrophage infiltration in breast cancer. This strategy was also found to inhibit metastatic seeding in the lung and to prolong survival in mice with tumors formed by transplanted human breast cancer cells[32](#cas14075-bib-0032){ref-type="ref"}or mouse melanoma cells.[33](#cas14075-bib-0033){ref-type="ref"} Administration effects of antibodies to CCL2 were associated with inhibition of the recruitment to the tumors of CCR2^+^ inflammatory monocytes.

Antibodies to human CCL2 have been evaluated for safety, pharmacokinetic‐pharmacodynamic profile, and antitumor activity in cancer patients. Phase 1 clinical trials (NCT00537368 and NCT01204996) and a phase 2 study (NCT00992186) for a mAb to human CCL2 (CNTO888, carlumab)[34](#cas14075-bib-0034){ref-type="ref"}, [35](#cas14075-bib-0035){ref-type="ref"}, [36](#cas14075-bib-0036){ref-type="ref"} showed that it induced a transient decrease in the concentration of CCL2 in serum, but that this decrease was followed by an increase to levels higher than pretreatment baseline values. Pharmacodynamics analysis indicated that, in contrast to its high affinity for CCL2 (dissociation constant of 15 pmol/L) in vitro, the affinity of CNTO888 for CCL2 was much higher (dissociation constant of 2.4 nmol/L) in patients, suggestive of a reduced capacity to inhibit CCL2 in vivo.[34](#cas14075-bib-0034){ref-type="ref"}

Another phase 2 clinical trial (NCT01015560) with a humanized mAb to CCR2 (MLN1202, plozalizumab) was conducted with regard to treatment of bone metastasis of unspecified tumors.[37](#cas14075-bib-0037){ref-type="ref"} MLN1202 was given to 44 patients with bone metastasis to evaluate its effects on tumor cell proliferation, monocyte‐macrophage trafficking, and osteoclast maturation. Urinary concentration of N‐telopeptide, a biomarker of bone turnover, was decreased in 14% of the treated patients, and serious adverse events developed in 7% of the patients. A phase 1 clinical trial (NCT02723006) of MLN1202 in combination with the immune‐checkpoint inhibitor nivolumab for patients with advanced melanoma was terminated as a result of the emergence of serious adverse events. Together, these results suggest that antibodies to CCL2 and CCR2 have limited potential for cancer therapy.

2.2. Small‐molecule compounds {#cas14075-sec-0004}
-----------------------------

As an alternative to neutralizing antibodies, chemical agents have been shown to restrain cancer progression by inhibiting the CCL2‐CCR2 axis. Treatment with one such small‐molecule antagonist of CCR2 (PF‐04136309) alone or in combination with gemcitabine slowed tumor progression and reduced the number of infiltrating TAM in mice subjected to orthotopic transplantation of established PDAC tumors.[38](#cas14075-bib-0038){ref-type="ref"} Similar results were obtained when PF‐04136309 was combined with FOLFIRINOX chemotherapy in mice.[39](#cas14075-bib-0039){ref-type="ref"} PF‐04136309 in combination with gemcitabine also completely inhibited metastasis of pancreatic cancer cells injected into mice through the tail vein.[40](#cas14075-bib-0040){ref-type="ref"} In addition, PF‐04136309 treatment significantly attenuated lung metastasis of lung squamous carcinomas cells injected i.v. in mice.[41](#cas14075-bib-0041){ref-type="ref"} Giving CCX872‐B, another small‐molecule antagonist of CCR2, prolonged overall survival in a mouse model of breast cancer, although it neither extended tumor‐free survival nor suppressed tumor growth.[42](#cas14075-bib-0042){ref-type="ref"}

On the basis of the preclinical findings for the potential of PF‐04136309 for treatment of pancreatic cancer, a phase 1 clinical trial (NCT01413022) was conducted for this agent in combination with FOLFIRINOX in patients with nonmetastatic PDAC.[43](#cas14075-bib-0043){ref-type="ref"} Incidence of adverse events of grade 3 or higher in patients treated with FOLFIRINOX plus PF‐04136309 was similar to that in those who received FOLFIRINOX alone. Treatment with PF‐04136309 prevented the PDAC‐mediated mobilization of bone marrow‐derived CCR2^+^ monocytes into the peripheral circulation, resulting in a decrease in the number of TAM. Approximately half of the patients treated with FOLFIRINOX plus PF‐04136309 achieved an objective tumor response, suggesting that such therapy is both effective and tolerable. A phase 1b/2 clinical study of PF‐04136309 in combination with nab‐paclitaxel and gemcitabine in patients with metastatic PDAC (NCT02732938) was terminated as a business‐related decision by Pfizer. Clinical trials of small‐molecule CCR2 blockers for patients with other inflammatory diseases such as insulin resistance, multiple sclerosis, nonalcoholic steatohepatitis, and rheumatoid arthritis have also been conducted (Table [1](#cas14075-tbl-0001){ref-type="table"}).

###### 

Structures, IC~50~, and clinical trials for C‐C chemokine receptor type 2 blockers

  Reagent                                        Structure                            Originator                                       IC~50~ (in vitro binding)   IC~50~ (chemotaxis)   Clinical trial                                 ClinicalTrials.gov   Status
  ---------------------------------------------- ------------------------------------ ------------------------------------------------ --------------------------- --------------------- ---------------------------------------------- -------------------- ---------------------------------
  15a                                            ![](CAS-110-2090-g004.jpg "image")                                                    50 nmol/L                   --                    --                                                                  
  AZD2423                                        ![](CAS-110-2090-g005.jpg "image")   AstraZeneca                                      2.6 nmol/L                  4.4 nmol/L            Chronic obstructive pulmonary disease (COPD)   NCT01153321          Completed (inhibition of)
  Chronic obstructive pulmonary disease (COPD)   NCT01215279                          Completed (no effect)                                                                                                                                                  
  Post‐traumatic neuralgia                       NCT01200524                          Completed (modest improvement)                                                                                                                                         
  Painful diabetic polyneuropathy                NCT01201317                          Completed (no effect)                                                                                                                                                  
  BMS741672                                      ![](CAS-110-2090-g006.jpg "image")   Bristol‐Myers Squibb                             1.4 nmol/L                  --                    Type 2 diabetes mellitus                       NCT00699790          Completed
  Neuropathic pain                               NCT00683423                          Completed                                                                                                                                                              
  BMS813160                                      ![](CAS-110-2090-g007.jpg "image")   Bristol‐Myers Squibb                             6.2 nmol/L                  0.8 nmol/L            Pancreatic ductal adenocarcinoma (PDAC)        NCT03496662          Recruiting
  Pancreatic ductal adenocarcinoma (PDAC)        NCT03767582                          Ongoing                                                                                                                                                                
  Colorectal cancer and pancreatic cancer        NCT03184870                          Recruiting                                                                                                                                                             
  Diabetic kidney disease                        NCT01752985                          Completed (no result published)                                                                                                                                        
  Accelerated intimal hyperplasia                NCT01049165                          Completed (no result published)                                                                                                                                        
  CAS 445479‐97‐0                                ![](CAS-110-2090-g008.jpg "image")   Bristol‐Myers Squibb                             5.1 nmol/L                  1 nmol/L              --                                                                  
  CCX140‐B                                       ![](CAS-110-2090-g009.jpg "image")   ChemoCentryx                                     17 nmol/L                   8 nmol/L              Diabetic nephropathy                           NCT01447147          Completed (modest improvement)
  Type 2 diabetes mellitus                       NCT01440257                          Completed (no result published)                                                                                                                                        
  Type 2 diabetes mellitus                       NCT01028963                          Completed (no result published)                                                                                                                                        
  Focal segmental glomerulosclerosis             NCT03536754                          Recruiting                                                                                                                                                             
  CCX872‐B                                       Undisclosed                          ChemoCentryx                                     3 nmol/L                    32 nmol/L             Pancreatic adenocarcinoma                      NCT02345408          Ongoing
  Cenicriviroc                                   ![](CAS-110-2090-g010.jpg "image")   National Institute for Health Research; Takeda   5.9 nmol/L                  --                    Nonalcoholic steatohepatitis (NASH)            NCT02217475          Completed (no result published)
  HIV‐1 infection                                NCT01092104                          Completed (no result published)                                                                                                                                        
  Nonalcoholic steatohepatitis (NASH)            NCT03028740                          Recruiting                                                                                                                                                             
  Nonalcoholic fatty liver disease (NAFLD)       NCT02330549                          Completed (no result published)                                                                                                                                        
  Primary sclerosing cholangitis                 NCT02653625                          Completed (modest improvement)                                                                                                                                         
  INCB3284                                       ![](CAS-110-2090-g011.jpg "image")   Incyte Corporation                               3.7 nmol/L                  4.7 nmol/L            --                                                                  
  INCB3344                                       ![](CAS-110-2090-g012.jpg "image")   Incyte Corporation                               5.1 nmol/L                  3.8 nmol/L            --                                                                  
  JNJ‐17166864                                   ![](CAS-110-2090-g013.jpg "image")   Johnson & Johnson                                --                          --                    Allergic rhinitis                              NCT00604123          Completed (no result published)
  JNJ‐41443532                                   ![](CAS-110-2090-g014.jpg "image")   Johnson & Johnson                                --                          --                    Type 2 diabetes mellitus                       NCT01230749          Completed (modest improvement)
  MK0812                                         ![](CAS-110-2090-g015.jpg "image")   Merck & Co.                                      3.2 nmol/L                  8 nmol/L              Rheumatoid arthritis                           NCT00542022          Completed (no result published)
  Multiple sclerosis                             NCT00239655                          Terminated                                                                                                                                                             
  PF04136309                                     ![](CAS-110-2090-g016.jpg "image")   Pfizer                                           5.2 nmol/L                  3.9 nmol/L            Metastatic pancreatic ductal adenocarcinoma    NCT02732938          Terminated
  Pancreatic adenocarcinoma                      NCT01413022                          Completed (no result published)                                                                                                                                        
  Osteoarthritic pain                            NCT00689273                          Completed (no result published)                                                                                                                                        
  Chronic hepatitis C infection                  NCT01226797                          Terminated                                                                                                                                                             
  PF04634817                                     ![](CAS-110-2090-g017.jpg "image")   Pfizer                                           3.68 nmol/L                 --                    Type 2 diabetes and overt nephropathy          NCT01712061          Completed (modest improvement)
  Renal insufficiency                            NCT01791855                          Completed (no result published)                                                                                                                                        
  Diabetic macular edema                         NCT01994291                          Terminated                                                                                                                                                             
  RO5234444                                      ![](CAS-110-2090-g018.jpg "image")   Roche                                            22 nmol/L                   50.2 nmol/L           --                                                                  
  RS504393                                       ![](CAS-110-2090-g019.jpg "image")   Roche                                            89 nmol/L                   330 nmol/L            --                                                                  
  RS102895                                       ![](CAS-110-2090-g020.jpg "image")   Roche                                            360 nmol/L                  1700 nmol/L           --                                                                  
  TLK19705                                       ![](CAS-110-2090-g021.jpg "image")   Telik, Inc.                                      --                          700 nmol/L            --                                                                  

\'‐\' indicates that there is no data available.

John Wiley & Sons, Ltd

3. CHEMICAL AND PHARMACOLOGICAL PROPERTIES OF PROPAGERMANIUM {#cas14075-sec-0005}
============================================================

Organogermanium compounds manifest various biological actions including antibacterial and antioxidant effects, effects on the blood circulation system, and anticancer activities. PGe, with the formula (C~3~H~5~GeO~3.5~)~*n*~, is the only approved medicine among such compounds. It was discovered in 1979 together with other organic germanium polymers, and it was approved for the treatment of chronic hepatitis B in Japan in 1994, having now been given to such patients for 25 years. PGe has the same essential formula as RGe (or Ge‐132), poly‐*trans*‐\[(2‐carboxyethyl) germasesquioxane\] or (C~18~H~30~Ge~6~O~21~)~*n*~, although the physicochemical properties of the two compounds are distinct.[44](#cas14075-bib-0044){ref-type="ref"} PGe is thus more susceptible to hydrolysis by water than is RGe. At low concentrations, PGe and RGe are hydrolyzed to the same monomer species. At high concentrations, however, whereas RGe is hydrolyzed to the same monomer, PGe is hydrolyzed to GeSP (Figure [2](#cas14075-fig-0002){ref-type="fig"}).

![Solid and water‐soluble forms of propagermanium (PGe) and repagermanium (RGe). GeSP, germanium straight‐chain polymer](CAS-110-2090-g002){#cas14075-fig-0002}

PGe exerts immunomodulatory effects through interaction with glycosylphosphatidylinositol‐anchored proteins associated with CCR2. It thus interrupts the CCL2‐CCR2 signaling pathway and thereby suppresses the chemotaxis of monocytes‐macrophages without disrupting the receptor‐ligand interaction.[45](#cas14075-bib-0045){ref-type="ref"} Inhibition of such signaling by treatment with PGe promotes retention of all leukocyte subsets---in particular, inflammatory monocytes---in bone marrow, resulting in a reciprocal reduction in the number of these cells in peripheral blood and consistent with the suppressive effect of PGe on a range of chronic inflammatory conditions mediated primarily by inflammatory monocytes and macrophages.

A double‐blind controlled trial of PGe was conducted with HBV antigen‐positive chronic hepatitis in the late 1980s.[46](#cas14075-bib-0046){ref-type="ref"} Titers of antibodies to HBV were significantly increased after treatment in the PGe group, whereas HBV antigen titers were significantly lower in the PGe group than in the placebo group. Serum HBV antigen levels and serum (ALT levels were significantly lower in the PGe group than in the control group at 12 and 16 weeks after treatment onset. PGe is also effective for the treatment of other types of liver injury in mice. Giving oral PGe thus inhibited the development of liver injury induced by injection of concanavalin A or lipopolysaccharide injection, *Corynebacterium parvum* infection or genetic deletion of fumarylacetoacetate hydrolase.[47](#cas14075-bib-0047){ref-type="ref"}, [48](#cas14075-bib-0048){ref-type="ref"}, [49](#cas14075-bib-0049){ref-type="ref"} PGe also has therapeutic effects in other inflammatory diseases such as atherosclerosis,[50](#cas14075-bib-0050){ref-type="ref"}, [51](#cas14075-bib-0051){ref-type="ref"} fibrosis,[52](#cas14075-bib-0052){ref-type="ref"}, [53](#cas14075-bib-0053){ref-type="ref"}, [54](#cas14075-bib-0054){ref-type="ref"} and obesity induced by a high‐fat diet.[55](#cas14075-bib-0055){ref-type="ref"}, [56](#cas14075-bib-0056){ref-type="ref"}, [57](#cas14075-bib-0057){ref-type="ref"}

4. PROPAGERMANIUM FOR TREATMENT OF CANCER {#cas14075-sec-0006}
=========================================

Recent studies have shown that interference with key mediators of metastatic development is a promising alternative strategy for cancer treatment. The CCL2‐CCR2 signaling pathway is an attractive therapeutic target in such an approach, given its key functions in metastasis described above. We previously showed that Fbxw7 (also known as Fbw7, Sel‐10, hCdc4, or hAgo), a receptor protein of SCF (Skp1‐Cul1‐F‐box protein)‐type ubiquitin ligases, suppresses cancer metastasis by inhibition of CCL2‐dependent inflammation.[58](#cas14075-bib-0058){ref-type="ref"} A low level of Fbxw7 in tumor cells and peripheral blood is associated with poor prognosis in cancer patients. Moreover, mice in which *Fbxw7* is specifically ablated in bone marrow (*Fbxw7* ^bmΔ/Δ^ mice) manifest enhanced metastasis of melanoma, lung carcinoma, and breast adenocarcinoma. Serum level of CCL2 was also increased in *Fbxw7* ^bmΔ/Δ^ mice compared with control mice both before and after orthotopic transplantation of breast cancer cells. In addition, the numbers of Ly6C^+^ Mo‐MDSC and F4/80^+^ macrophages were increased in peripheral blood and at sites of metastasis in *Fbxw7* ^bmΔ/Δ^ mice (Figure [3](#cas14075-fig-0003){ref-type="fig"}).

![Model for the promotion of cancer metastasis by loss of Fbxw7 in the host environment and its suppression by treatment with propagermanium (PGe). Excessive signaling by Notch1 due to the impairment of its degradation as a result of Fbxw7 ablation gives rise to increased production of chemokine C‐C motif chemokine 2 (CCL2). Consequent recruitment of monocytic myeloid‐derived suppressor cells (Mo‐MDSC) and tumor‐associated macrophages (TAM) facilitates metastatic tumor growth. PGe suppresses CCL2‐dependent recruitment of Mo‐MDSC and TAM and thereby attenuates cancer metastasis. CCR2, C‐C chemokine receptor type 2](CAS-110-2090-g003){#cas14075-fig-0003}

Giving PGe significantly attenuated metastasis of melanoma cells and breast cancer cells in *Fbxw7* ^bmΔ/Δ^ mice, with the size of metastatic nodules of breast adenocarcinoma in the lungs being reduced.[58](#cas14075-bib-0058){ref-type="ref"} Such treatment also reduced the number of Ly6C^+^ Mo‐MDSC found in the lungs of *Fbxw7* ^bmΔ/Δ^ mice after transplantation of breast cancer cells (Figure [3](#cas14075-fig-0003){ref-type="fig"}).

Treatment with PGe in a mouse model of colon carcinogenesis reduced the number and size of tumors as well as the number of TAM, and it attenuated adenocarcinomatous changes in the colon tumors.[59](#cas14075-bib-0059){ref-type="ref"} A phase 2 clinical trial (UMIN000017123) is underway to assess the efficacy of PGe in 15 patients with untreatable advanced or metastatic gastric cancer. Another study found that PGe treatment in 10 multiple myeloma patients resulted in complete remission in two patients, partial remission in two patients, stable disease in four patients, and progressive disease in two patients.[60](#cas14075-bib-0060){ref-type="ref"} After discontinuation of PGe, the multiple myeloma progressed in two patients who had achieved stable disease and in the two patients who had achieved partial remission. Phase 1 studies are also ongoing to evaluate the safety and effectiveness of PGe for patients with breast cancer (UMIN000022494), pancreatic cancer (UMIN000017715), and colorectal cancer (UMIN000022129).

5. CONCLUSIONS {#cas14075-sec-0007}
==============

The CCL2‐CCR2 signaling pathway plays a central role in inflammatory diseases including cancer metastasis. Treatment targeted to CCR2 such as that with PGe alleviates pathological phenotypes associated with these diseases. PGe has been approved for the treatment of hepatitis B in Japan, and its bioavailability and safety have been established. Drug repositioning, which aims to identify new indications for existing drugs, has been gaining popularity as an approach to drug discovery. PGe is thus a candidate for drug repositioning with regard to its suppressive effect on cancer metastasis. Further studies will determine whether this agent is truly effective for the treatment of cancer.
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